Stock APGE APOGEE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Apogee Therapeutics, Inc.

Equities

APGE

US03770N1019

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-28 pm EDT 		5-day change 1st Jan Change
47.86 USD -0.35% Intraday chart for Apogee Therapeutics, Inc. -2.74% +71.30%
May. 28 Apogee Therapeutics, Inc. Appoints Lisa Bollinger to Its Board of Directors CI
May. 15 Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases CI

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Apogee Therapeutics, Inc. Appoints Lisa Bollinger to Its Board of Directors
Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
Apogee Therapeutics' Q1 Net Loss Widens
Apogee Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Ra Antibody for the Treatment of Chronic Obstructive Pulmonary Disease and Other Inflammatory Diseases
Apogee Therapeutics Prices Upsized $420 Million Share Offering
Sector Update: Health Care Stocks Advance Wednesday Afternoon
Apogee Therapeutics Shares Rise After Jefferies Raises Price Target
Apogee Therapeutics Unveils $350 Million Share Offering
Sector Update: Health Care Stocks Retreating Late Afternoon
Sector Update: Health Care Stocks Lower Tuesday Afternoon
Top Midday Gainers
Sector Update: Health Care
Apogee Therapeutics Shares Surge After Phase 1 Atopic Dermatitis Trial Data, Wedbush Price Target Raise
Apogee Therapeutics Says Phase 1 Study of Atopic Dermatitis Drug Candidate Exceeds Objectives
Apogee Therapeutics' Q4 Net Loss Widens
Apogee Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Apogee Therapeutics, Inc. Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases
Apogee Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Apogee Therapeutics, Inc. and Paragon Therapeutics, Inc. Announce Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology Congress
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. APGE Stock
  4. News Apogee Therapeutics, Inc.
  5. Other languages